Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals

From Biology to the Clinic: Optimizing Rationale, Development & Translation of Bispecific ADCs

By | 8 June 2026

Breaking down biology rationale for pursuing bispecific ADC development and selecting target pairings
Evaluating preclinical profiles of bispecific ADCs highlighting favorable efficacy and tolerability profiles against monospecific therapies
Laying out considerations and strategy to optimize successful translational through biomarker and clinical development strategies